Under 10% of patients eligible to benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it publishes its inaugural advice on the drugs.
With more than one billion people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
Per forecasts, over two billion will be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be treated with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant hurdles to universal availability to the treatments that can assist patients in reducing considerable weight, explains the organization.
Despite the present most favorable scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice encourages governments and firms to expand access, through approaches including patent sharing.
A patent on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
These medications replicate a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so people consume fewer calories.
Patients typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research points to patients may see weight return after a year of stopping the medication, as their usual food cravings come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight concerns individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
A financial strategist with over a decade of experience in wealth management and investment planning, dedicated to empowering others.
Rita Jenkins
Rita Jenkins
Rita Jenkins